Cerebrolysin

A porcine-derived neuropeptide preparation used clinically in parts of Europe and Asia for stroke and dementia.

Cerebrolysin is classified as a porcine brain-derived peptide preparation. Its current development status is: approved in several countries. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.

The Peptide Institute tracks Cerebrolysin because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.